Topical BCG for recurrent superficial bladder cancer.
D000287:Administration, Topical; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy*; D014555:Urination Disorders / Q000209:etiology
D001500:BCG Vaccine; D006680:HLA Antigens